the lung cancer biomarker analysis currently includes fish testing for alk and ros1 gene rearrangements and mutation analysis of the t790m , deletion 19 , and l858r mutations of the epidermal growth factor receptor , or egfr , gene as well as b-raf and k-ras using our target-selector platform . the l858r mutation of the egfr gene and exon 19 deletions as activators of egfr kinase activity are associated with the drugs tarceva® , gilotrif® and iressa® . the codon 12 and 13 mutations of the k-ras gene are found in patients whose tumors are unlikely to respond to the egfr kinase inhibitors such as erbitux® and vectibix® . for lung cancer , we also offer a resistance panel assay consisting of the biomarkers met , her2 ( both of which we perform using our technology for ctcs ) and t790m which is performed using ctdna in plasma . this assay could be used by physicians to identify the mechanism causing disease progression for patients with nsclc who are being treated with tki therapy and therefore could qualify for inclusion in a clinical trial . fibroblast growth receptor 1 , or fgfr1 , amplification is offered using our ctc technology . fgfr1 is present in several tumor types , including both nsclc and sclc and has been shown to be a prognostic indicator of progression . fgfr1 is also a key target for many drugs which are in clinical development . mutations of the b-raf gene are associated with zelboraf® and tafinlar® , which are both approved for treating patients with melanoma and are in clinical trials for lung cancer . we offer testing for b-raf on blood using our ctdna offering . 57 we plan to add other biomarker analyses on blood samples to our current assays and our planned future target-selector assays as their relevance is demonstrated in clinical trials and or included in guidelines used by physicians to make treatment decisions . our revenue generating efforts are focused in three areas : · providing clinical testing that oncologists use in order to determine the best treatment plan for their patients ; · providing clinical trial , research and development services to biopharma companies developing cancer therapies ; and · licensing our proprietary testing and or technologies to partners in the united states and abroad . key factors affecting our results of operations and financial condition our overall long-term growth plan depends on our ability to continue to develop and commercialize assays through our clia-certified , cap-accredited , and state-licensed laboratory . we have launched our target-selector offering for breast cancer , lung cancer , gastric cancer , colorectal cancer , prostate cancer , and melanoma , and plan to continue to launch a series of cancer diagnostic assays for different predictive biomarkers assays in the united states as ldts performed in our laboratory , and enhance revenue for these products through the efforts of our sales and marketing organization , which we plan to expand . our sales strategy is to engage oncologists and other physicians in the united states at private and group practices , hospitals and cancer centers . we also plan to evaluate potential opportunities for the commercialization of our products in other countries . in addition to testing for physicians and their patients , we plan to offer clinical trials testing and research services to help increase the efficiency and economic viability of clinical trials for pharmaceutical and biopharmaceutical companies and clinical research organizations both within and outside of the united states . we are currently exploring the possibility of introducing ctdna technology outside the united states as part of ce-marked ivd test kits and or testing systems utilizing our target-selector technologies . we plan to cooperate with partners on accessing markets internationally . we plan for this to be accomplished either through partnerships with local groups and distributors or the development of ivds and or test systems , including instrumentation . we also have a research and development program focused on technology enhancements , novel platform development , and evaluating clinical applications for our cancer diagnostic tests in different cancer types and clinical settings . to facilitate market adoption of our assays , we anticipate having to successfully complete additional clinical utility studies with clinical samples to generate clinical utility data and then publish our results in peer-reviewed scientific journals . our ability to complete such clinical studies is dependent upon our ability to leverage our collaborative relationships with leading institutions to facilitate our research , to conduct the appropriate clinical studies and to obtain favorable clinical data . we collaborate with physicians and researchers at sarah cannon research institute , baylor college of medicine , the university of texas md anderson cancer center , the dana-farber cancer institute , the university of california , san diego , university of california , irvine , washington university , university of colorado , yale university and columbia university and plan to expand our collaborative relationships to include other key thought leaders at other institutions for the cancer types we target with our target selector commercialized assays and our planned future assays . such relationships help us develop and validate the effectiveness and utility of our commercialized assays and our planned future assays in specific clinical settings and provide us access to patient samples and data . we believe that the factors discussed in the following paragraphs have had and are expected to continue to have a material impact on our results of operations and financial condition . revenues we accessioned 1,608 commercial cases during the year ended december 31 , 2015 as compared to 402 commercial cases for the same period in 2014 , an increase of 1,206 cases , or 300 % . revenues from commercial cases are recognized as collected , and the expected collection period for a commercial case often extends beyond the end of the quarter in which accessioned , with multiple payments received per case . story_separator_special_tag change in fair value of warrant liability the decrease in the non-cash loss of approximately $ 202,000 for the year ended december 31 , 2015 as compared to the same period in 2014 is primarily due to a fewer number of estimated average warrants outstanding , as the majority of the outstanding liability-classified warrants were reclassified to equity upon the closing of our initial public offering in february 2014. income taxes over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes . as a result , we have accumulated significant net operating losses and other deferred tax assets . because of our history of losses and the uncertainty as to the realization of those deferred tax assets , a full valuation allowance has been recognized . we do not expect to report a provision for income taxes until we have a history of earnings , if ever , that would support the realization of our deferred tax assets . we have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation , due to the complexity and cost associated with such a study , and the fact that there may be additional ownership changes in the future , however , we believe an ownership change likely occurred during 2015 . as a result , we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero . 62 inflation we do not believe that inflation has had a material adverse impact on our business or operating results during the periods presented . story_separator_special_tag style= `` font-size:10pt ; font-family : times new roman ; font-weight : normal ; font-style : normal ; text-transform : none ; font-variant : normal ; `` > on stock to aspire capital . aspire capital has no right to require any sales by us , but is obligated to make purchases from us as directed by us in accordance with the common stock purchase agreement . there are no limitations on use of proceeds , financia l or business covenants , restrictions on future fundings , rights of first refusal , participation rights , penalties or liquidated damages in the common stock purchase agreement . in consideration for entering into , and concurrently with the execution of , th e common stock purchase agreement , we issued to aspire capital 165,000 shares of our common stock . the common stock purchase agreement may be terminated by us at any time , at our discretion , without any cost to us . aspire capital has agreed that neither i t nor any of its agents , representatives and affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the common stock purchase agreement . any proceeds we receive under the c ommon stock purchase agremeent are expected to be used for working capital and general corporate purposes . approximately $ 14.0 million , or up to 2,984,122 shares , remains available to be issued to aspire capital under this agreement as of march 3 , 2016. note and warrant financings from february 2011 to november 2012 , we sold secured convertible promissory notes with an aggregate principal amount of approximately $ 12.3 million , together with warrants that subsequently became exercisable for 108,786 shares of our common stock at an exercise price of $ 10.00 per share , to 11 accredited investors , for aggregate gross proceeds of approximately $ 12.3 million . from january 2012 to december 2012 , we sold promissory notes with an aggregate principal amount of approximately $ 6.0 million , together with warrants that subsequently became exercisable for 52,557 shares of our common stock to five accredited investors at an exercise price of $ 10.00 per share , for aggregate gross proceeds of approximately $ 6.0 million . these promissory notes were converted into shares of our common stock upon the closing of our initial public offering . from december 2012 through january 2014 , we sold promissory notes with an aggregate principal amount of approximately $ 5.2 million , together with warrants that subsequently became exercisable for 258,249 shares of our common stock at an exercise price of $ 10.00 per share , to 14 accredited investors , for aggregate gross proceeds of approximately $ 5.2 million . other debt and warrant financings in july 2013 , we entered into a revolving line of credit with ubs bank usa in the initial amount of $ 1.5 million . the maximum amount of this line of credit was subsequently increased to approximately $ 2.6 million . interest accrued daily on the outstanding balance and was paid monthly at a variable rate , which was 2.75 % over the 30 day libor rate , or an effective annual interest rate of 2.92 % . ubs bank usa had the right to terminate the revolving line of credit at any time , and if it did , all amounts drawn under the revolving line of credit would be immediately payable . an affiliate of our director david f. hale , and an affiliate of claire k. t. reiss , a 5 % shareholder and at the time a director , an affiliate of our director edward neff , an affiliate of our director bruce e. gerhardt , and an affiliate of our director ivor royston guaranteed the loan and pledged financial assets to ubs bank usa to secure their guaranties . in return , we issued common stock warrants to the guarantors . the number of shares underlying the associated common stock warrants were fixed so that such warrants became exercisable

liquidity and capital resources we are actively working to improve our financial position and enable the growth of our business , by raising new capital and generating revenues . equity financings pursuant to an underwriting agreement dated february 4 , 2014 between us and aegis capital corp. , or aegis , as representative of the several underwriters named therein , an initial public offering of 1,900,000 shares of common stock at $ 10.00 per share was effected on february 5 , 2014. the closing of the sale of these shares to the underwriters occurred on february 10 , 2014. we received , after deducting underwriting discounts and additional costs paid to the underwriters , approximately $ 17.4 million of net cash proceeds from the sale of these 1,900,000 shares . the total increase in capital as a result of the sale of these shares was approximately $ 16.5 million after deducting $ 0.9 million of additional non-underwriter costs incurred that are netted against these proceeds under applicable accounting guidance . in addition , designees of aegis were issued warrants to buy ( in the aggregate ) up to 95,000 shares of common stock at $ 12.50 per share with a term of five years . pursuant to an underwriting agreement dated february 9 , 2015 between us , aegis and feltl and company , as underwriters named therein , a public offering of 8,000,000 shares of our common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $ 1.25. the estimated grant date fair value of these warrants of $ 7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we are actively working to improve our financial position and enable the growth of our business , by raising new capital and generating revenues . equity financings pursuant to an underwriting agreement dated february 4 , 2014 between us and aegis capital corp. , or aegis , as representative of the several underwriters named therein , an initial public offering of 1,900,000 shares of common stock at $ 10.00 per share was effected on february 5 , 2014. the closing of the sale of these shares to the underwriters occurred on february 10 , 2014. we received , after deducting underwriting discounts and additional costs paid to the underwriters , approximately $ 17.4 million of net cash proceeds from the sale of these 1,900,000 shares . the total increase in capital as a result of the sale of these shares was approximately $ 16.5 million after deducting $ 0.9 million of additional non-underwriter costs incurred that are netted against these proceeds under applicable accounting guidance . in addition , designees of aegis were issued warrants to buy ( in the aggregate ) up to 95,000 shares of common stock at $ 12.50 per share with a term of five years . pursuant to an underwriting agreement dated february 9 , 2015 between us , aegis and feltl and company , as underwriters named therein , a public offering of 8,000,000 shares of our common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $ 1.25. the estimated grant date fair value of these warrants of $ 7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering .
```    
 Suspicious Activity Report : the lung cancer biomarker analysis currently includes fish testing for alk and ros1 gene rearrangements and mutation analysis of the t790m , deletion 19 , and l858r mutations of the epidermal growth factor receptor , or egfr , gene as well as b-raf and k-ras using our target-selector platform . the l858r mutation of the egfr gene and exon 19 deletions as activators of egfr kinase activity are associated with the drugs tarceva® , gilotrif® and iressa® . the codon 12 and 13 mutations of the k-ras gene are found in patients whose tumors are unlikely to respond to the egfr kinase inhibitors such as erbitux® and vectibix® . for lung cancer , we also offer a resistance panel assay consisting of the biomarkers met , her2 ( both of which we perform using our technology for ctcs ) and t790m which is performed using ctdna in plasma . this assay could be used by physicians to identify the mechanism causing disease progression for patients with nsclc who are being treated with tki therapy and therefore could qualify for inclusion in a clinical trial . fibroblast growth receptor 1 , or fgfr1 , amplification is offered using our ctc technology . fgfr1 is present in several tumor types , including both nsclc and sclc and has been shown to be a prognostic indicator of progression . fgfr1 is also a key target for many drugs which are in clinical development . mutations of the b-raf gene are associated with zelboraf® and tafinlar® , which are both approved for treating patients with melanoma and are in clinical trials for lung cancer . we offer testing for b-raf on blood using our ctdna offering . 57 we plan to add other biomarker analyses on blood samples to our current assays and our planned future target-selector assays as their relevance is demonstrated in clinical trials and or included in guidelines used by physicians to make treatment decisions . our revenue generating efforts are focused in three areas : · providing clinical testing that oncologists use in order to determine the best treatment plan for their patients ; · providing clinical trial , research and development services to biopharma companies developing cancer therapies ; and · licensing our proprietary testing and or technologies to partners in the united states and abroad . key factors affecting our results of operations and financial condition our overall long-term growth plan depends on our ability to continue to develop and commercialize assays through our clia-certified , cap-accredited , and state-licensed laboratory . we have launched our target-selector offering for breast cancer , lung cancer , gastric cancer , colorectal cancer , prostate cancer , and melanoma , and plan to continue to launch a series of cancer diagnostic assays for different predictive biomarkers assays in the united states as ldts performed in our laboratory , and enhance revenue for these products through the efforts of our sales and marketing organization , which we plan to expand . our sales strategy is to engage oncologists and other physicians in the united states at private and group practices , hospitals and cancer centers . we also plan to evaluate potential opportunities for the commercialization of our products in other countries . in addition to testing for physicians and their patients , we plan to offer clinical trials testing and research services to help increase the efficiency and economic viability of clinical trials for pharmaceutical and biopharmaceutical companies and clinical research organizations both within and outside of the united states . we are currently exploring the possibility of introducing ctdna technology outside the united states as part of ce-marked ivd test kits and or testing systems utilizing our target-selector technologies . we plan to cooperate with partners on accessing markets internationally . we plan for this to be accomplished either through partnerships with local groups and distributors or the development of ivds and or test systems , including instrumentation . we also have a research and development program focused on technology enhancements , novel platform development , and evaluating clinical applications for our cancer diagnostic tests in different cancer types and clinical settings . to facilitate market adoption of our assays , we anticipate having to successfully complete additional clinical utility studies with clinical samples to generate clinical utility data and then publish our results in peer-reviewed scientific journals . our ability to complete such clinical studies is dependent upon our ability to leverage our collaborative relationships with leading institutions to facilitate our research , to conduct the appropriate clinical studies and to obtain favorable clinical data . we collaborate with physicians and researchers at sarah cannon research institute , baylor college of medicine , the university of texas md anderson cancer center , the dana-farber cancer institute , the university of california , san diego , university of california , irvine , washington university , university of colorado , yale university and columbia university and plan to expand our collaborative relationships to include other key thought leaders at other institutions for the cancer types we target with our target selector commercialized assays and our planned future assays . such relationships help us develop and validate the effectiveness and utility of our commercialized assays and our planned future assays in specific clinical settings and provide us access to patient samples and data . we believe that the factors discussed in the following paragraphs have had and are expected to continue to have a material impact on our results of operations and financial condition . revenues we accessioned 1,608 commercial cases during the year ended december 31 , 2015 as compared to 402 commercial cases for the same period in 2014 , an increase of 1,206 cases , or 300 % . revenues from commercial cases are recognized as collected , and the expected collection period for a commercial case often extends beyond the end of the quarter in which accessioned , with multiple payments received per case . story_separator_special_tag change in fair value of warrant liability the decrease in the non-cash loss of approximately $ 202,000 for the year ended december 31 , 2015 as compared to the same period in 2014 is primarily due to a fewer number of estimated average warrants outstanding , as the majority of the outstanding liability-classified warrants were reclassified to equity upon the closing of our initial public offering in february 2014. income taxes over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes . as a result , we have accumulated significant net operating losses and other deferred tax assets . because of our history of losses and the uncertainty as to the realization of those deferred tax assets , a full valuation allowance has been recognized . we do not expect to report a provision for income taxes until we have a history of earnings , if ever , that would support the realization of our deferred tax assets . we have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation , due to the complexity and cost associated with such a study , and the fact that there may be additional ownership changes in the future , however , we believe an ownership change likely occurred during 2015 . as a result , we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero . 62 inflation we do not believe that inflation has had a material adverse impact on our business or operating results during the periods presented . story_separator_special_tag style= `` font-size:10pt ; font-family : times new roman ; font-weight : normal ; font-style : normal ; text-transform : none ; font-variant : normal ; `` > on stock to aspire capital . aspire capital has no right to require any sales by us , but is obligated to make purchases from us as directed by us in accordance with the common stock purchase agreement . there are no limitations on use of proceeds , financia l or business covenants , restrictions on future fundings , rights of first refusal , participation rights , penalties or liquidated damages in the common stock purchase agreement . in consideration for entering into , and concurrently with the execution of , th e common stock purchase agreement , we issued to aspire capital 165,000 shares of our common stock . the common stock purchase agreement may be terminated by us at any time , at our discretion , without any cost to us . aspire capital has agreed that neither i t nor any of its agents , representatives and affiliates shall engage in any direct or indirect short-selling or hedging of our common stock during any time prior to the termination of the common stock purchase agreement . any proceeds we receive under the c ommon stock purchase agremeent are expected to be used for working capital and general corporate purposes . approximately $ 14.0 million , or up to 2,984,122 shares , remains available to be issued to aspire capital under this agreement as of march 3 , 2016. note and warrant financings from february 2011 to november 2012 , we sold secured convertible promissory notes with an aggregate principal amount of approximately $ 12.3 million , together with warrants that subsequently became exercisable for 108,786 shares of our common stock at an exercise price of $ 10.00 per share , to 11 accredited investors , for aggregate gross proceeds of approximately $ 12.3 million . from january 2012 to december 2012 , we sold promissory notes with an aggregate principal amount of approximately $ 6.0 million , together with warrants that subsequently became exercisable for 52,557 shares of our common stock to five accredited investors at an exercise price of $ 10.00 per share , for aggregate gross proceeds of approximately $ 6.0 million . these promissory notes were converted into shares of our common stock upon the closing of our initial public offering . from december 2012 through january 2014 , we sold promissory notes with an aggregate principal amount of approximately $ 5.2 million , together with warrants that subsequently became exercisable for 258,249 shares of our common stock at an exercise price of $ 10.00 per share , to 14 accredited investors , for aggregate gross proceeds of approximately $ 5.2 million . other debt and warrant financings in july 2013 , we entered into a revolving line of credit with ubs bank usa in the initial amount of $ 1.5 million . the maximum amount of this line of credit was subsequently increased to approximately $ 2.6 million . interest accrued daily on the outstanding balance and was paid monthly at a variable rate , which was 2.75 % over the 30 day libor rate , or an effective annual interest rate of 2.92 % . ubs bank usa had the right to terminate the revolving line of credit at any time , and if it did , all amounts drawn under the revolving line of credit would be immediately payable . an affiliate of our director david f. hale , and an affiliate of claire k. t. reiss , a 5 % shareholder and at the time a director , an affiliate of our director edward neff , an affiliate of our director bruce e. gerhardt , and an affiliate of our director ivor royston guaranteed the loan and pledged financial assets to ubs bank usa to secure their guaranties . in return , we issued common stock warrants to the guarantors . the number of shares underlying the associated common stock warrants were fixed so that such warrants became exercisable

